对于血友病B的Fidanacogene Elaparvovec - 一个多年的随访研究
John E J Rasko1,2, Benjamin J Samelson-Jones3,4, Lindsey A George3,4
1University of Sydney, Central Clinical School, Faculty of Medicine and Health, Sydney.
The New England journal of medicine
|April 16, 2025
概括
菲达纳可 (Fidanacogene elaparvovec) 基因疗法在B型血友病患者中证明了长期的安全性和有效性. 治疗维持了XIX因子的活性,在3至6年内显著减少了出血事件.
科学领域:
- 基因治疗 基因治疗
- 血液学 血液学 血液学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 血友病B是一种遗传性出血疾病,是由因子IX缺乏引起的.
- 菲达诺基因 (Fidanacogene elaparvovec) 是一种腺相关病毒 (AAV) 载体,其向的是高活性因子IX变体的持续表达.
- 在此之前,对fidanacogene elaparvovec的长期安全性和有效性数据是未知的.
研究的目的:
- 评估fidanacogene elaparvovec在患有乙型血友病的患者中的长期安全性和疗效.
- 在延长的随访期间评估不良事件,XIX因子活性和年均出血率.
主要方法:
- 进行了一项为期12个月的研究,随后进行了为期5年的随访.
- 15名患有严重或中度严重B型血友病的参与者接受了fidanacogene elaparvovec (5x10^11vg/kg).
- 安全终点包括不良事件和实验室测量;疗效终点包括年均出血率和XIX因子活性.
主要成果:
- 14名参与者完成了至少3年的随访 (中位数为5.5年).
- 1年后没有报告与治疗相关的不良事件或因子IX抑制剂.
- 平均因子IX活性仍处于轻度血友病范围,年平均出血率低于1;10名参与者没有治疗出血发作.
- 肝脏监测没有显示出癌症,但在4名参与者中发现了肥胖症; 一名参与者有先前存在的肝脏疾病显示纤维化进展.
结论:
- 费达纳可 (Fidanacogene elaparvovec) 在3至6年内表现出良好的安全性,没有或轻微的不良反应.
- 在低静脉注射AAV剂量 (5x10^11vg/kg) 维持长期疗效.
- 这项研究支持fidanacogene elaparvovec作为对血友病B的潜在长期治疗方法.
相关概念视频
Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Clot Retraction and Fibrinolysis
10.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
567
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
567
Bioavailability Study Design: Single Versus Multiple Dose Studies
342
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
342
Bioequivalence studies: Biowaivers
406
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
406
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
380
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
380


